These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 20494931)
1. Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial. de Witte T; Hagemeijer A; Suciu S; Belhabri A; Delforge M; Kobbe G; Selleslag D; Schouten HC; Ferrant A; Biersack H; Amadori S; Muus P; Jansen JH; Hellström-Lindberg E; Kovacsovics T; Wijermans P; Ossenkoppele G; Gratwohl A; Marie JP; Willemze R Haematologica; 2010 Oct; 95(10):1754-61. PubMed ID: 20494931 [TBL] [Abstract][Full Text] [Related]
2. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. de Witte T; Suciu S; Verhoef G; Labar B; Archimbaud E; Aul C; Selleslag D; Ferrant A; Wijermans P; Mandelli F; Amadori S; Jehn U; Muus P; Boogaerts M; Zittoun R; Gratwohl A; Zwierzina H; Hagemeijer A; Willemze R Blood; 2001 Oct; 98(8):2326-31. PubMed ID: 11588026 [TBL] [Abstract][Full Text] [Related]
3. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. Zittoun RA; Mandelli F; Willemze R; de Witte T; Labar B; Resegotti L; Leoni F; Damasio E; Visani G; Papa G N Engl J Med; 1995 Jan; 332(4):217-23. PubMed ID: 7808487 [TBL] [Abstract][Full Text] [Related]
6. Outcomes of Intermediate Risk Karyotype Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared With Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-score Adjusted Analysis. Limvorapitak W; Barnett MJ; Hogge DE; Forrest DL; Nevill TJ; Narayanan S; Power MM; Nantel SH; Broady R; Song KW; Toze CL; Mourad YA; Sutherland HJ; Gerrie AS; White J; Sanford DS Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e481-e491. PubMed ID: 30100330 [TBL] [Abstract][Full Text] [Related]
7. Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Salvatore D; Labopin M; Ruggeri A; Battipaglia G; Ghavamzadeh A; Ciceri F; Blaise D; Arcese W; Sociè G; Bourhis JH; Van Lint MT; Bruno B; Huynh A; Santarone S; Deconinck E; Mohty M; Nagler A Haematologica; 2018 Aug; 103(8):1317-1328. PubMed ID: 29748438 [TBL] [Abstract][Full Text] [Related]
8. The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study. Klusmann JH; Reinhardt D; Zimmermann M; Kremens B; Vormoor J; Dworzak M; Creutzig U; Klingebiel T Haematologica; 2012 Jan; 97(1):21-9. PubMed ID: 21933851 [TBL] [Abstract][Full Text] [Related]
9. Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype. Baron F; Stevens-Kroef M; Kicinski M; Meloni G; Muus P; Marie JP; Halkes CJM; Thomas X; Vrhovac R; Albano F; Lefrère F; Sica S; Mancini M; Venditti A; Hagemeijer A; Jansen JH; Amadori S; de Witte T; Willemze R; Suciu S Haematologica; 2019 Jun; 104(6):1168-1175. PubMed ID: 30523055 [TBL] [Abstract][Full Text] [Related]
10. Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation. Koenecke C; Göhring G; de Wreede LC; van Biezen A; Scheid C; Volin L; Maertens J; Finke J; Schaap N; Robin M; Passweg J; Cornelissen J; Beelen D; Heuser M; de Witte T; Kröger N; Haematologica; 2015 Mar; 100(3):400-8. PubMed ID: 25552702 [TBL] [Abstract][Full Text] [Related]
11. A Study of Human Leukocyte Antigen Mismatched Cellular Therapy (Stem Cell Microtransplantation) in High-Risk Myelodysplastic Syndrome or Transformed Acute Myelogenous Leukemia. Hu KX; Sun QY; Guo M; Qiao JX; Yu CL; Qiao JH; Dong Z; Sun WJ; Zuo HL; Huang YJ; Cai B; Ai HS Stem Cells Transl Med; 2016 Apr; 5(4):524-9. PubMed ID: 26838271 [TBL] [Abstract][Full Text] [Related]
12. The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921). Oosterveld M; Suciu S; Verhoef G; Labar B; Belhabri A; Aul C; Selleslag D; Ferrant A; Wijermans P; Mandelli F; Amadori S; Jehn U; Muus P; Zittoun R; Hess U; Anak O; Beeldens F; Willemze R; de Witte T Leukemia; 2003 May; 17(5):859-68. PubMed ID: 12750698 [TBL] [Abstract][Full Text] [Related]
13. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Suciu S; Mandelli F; de Witte T; Zittoun R; Gallo E; Labar B; De Rosa G; Belhabri A; Giustolisi R; Delarue R; Liso V; Mirto S; Leone G; Bourhis JH; Fioritoni G; Jehn U; Amadori S; Fazi P; Hagemeijer A; Willemze R; Blood; 2003 Aug; 102(4):1232-40. PubMed ID: 12714526 [TBL] [Abstract][Full Text] [Related]
14. A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Groupe Français des Myélodysplasies. Group Ouest-Est d'étude des Leucémies aiguës myéloïdes. Wattel E; Solary E; Leleu X; Dreyfus F; Brion A; Jouet JP; Hoang-Ngoc L; Maloisel F; Guerci A; Rochant H; Gratecos N; Casassus P; Janvier M; Brice P; Lepelley P; Fenaux P Leukemia; 1999 Apr; 13(4):524-9. PubMed ID: 10214857 [TBL] [Abstract][Full Text] [Related]
15. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. Schmid C; Schleuning M; Ledderose G; Tischer J; Kolb HJ J Clin Oncol; 2005 Aug; 23(24):5675-87. PubMed ID: 16110027 [TBL] [Abstract][Full Text] [Related]
16. Treatment of primary acute myeloid leukemia: results of a prospective multicenter trial including high-dose cytarabine or stem cell transplantation as post-remission strategy. Brunet S; Esteve J; Berlanga J; Ribera JM; Bueno J; Martí JM; Bargay J; Guardia R; Juliá A; Granena A; Montserrat E; Sierra J; Haematologica; 2004 Aug; 89(8):940-9. PubMed ID: 15339677 [TBL] [Abstract][Full Text] [Related]
17. Autologous blood cell transplantation versus HLA-identical sibling transplantation for acute myeloid leukemia in first complete remission: a registry study from the Center for International Blood and Marrow Transplantation Research. Keating A; DaSilva G; Pérez WS; Gupta V; Cutler CS; Ballen KK; Cairo MS; Camitta BM; Champlin RE; Gajewski JL; Lazarus HM; Lill M; Marks DI; Nabhan C; Schiller GJ; Socie G; Szer J; Tallman MS; Weisdorf DJ Haematologica; 2013 Feb; 98(2):185-92. PubMed ID: 22983587 [TBL] [Abstract][Full Text] [Related]
18. A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies. Spitzer B; Jakubowski AA; Papadopoulos EB; Fuller K; Hilden PD; Young JW; Barker JN; Koehne G; Perales MA; Hsu KC; van den Brink MR; Kernan NA; Prockop SE; Scaradavou A; Castro-Malaspina H; O'Reilly RJ; Boulad F Biol Blood Marrow Transplant; 2017 Dec; 23(12):2088-2095. PubMed ID: 28711727 [TBL] [Abstract][Full Text] [Related]
19. Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). de Witte T; Hermans J; Vossen J; Bacigalupo A; Meloni G; Jacobsen N; Ruutu T; Ljungman P; Gratwohl A; Runde V; Niederwieser D; van Biezen A; Devergie A; Cornelissen J; Jouet JP; Arnold R; Apperley J Br J Haematol; 2000 Sep; 110(3):620-30. PubMed ID: 10997974 [TBL] [Abstract][Full Text] [Related]
20. Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial. Bornhäuser M; Schliemann C; Schetelig J; Röllig C; Kramer M; Glass B; Platzbecker U; Burchert A; Hänel M; Müller LP; Klein S; Bug G; Beelen D; Rösler W; Schäfer-Eckart K; Schmid C; Jost E; Lenz G; Tischer J; Spiekermann K; Pfirrmann M; Serve H; Stölzel F; Alakel N; Middeke JM; Thiede C; Ehninger G; Berdel WE; Stelljes M JAMA Oncol; 2023 Apr; 9(4):519-526. PubMed ID: 36757706 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]